Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) is an agent with adrenotoxic effect, which is able to block cortisol synthesis. This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown. We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells. Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination. This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells. Cell cycle analysis showed that IR alone and IR/o,p'-DDD in combination induced the cell accumulation in the G2 phase. At 120 h after IR, the cells were able to recover the IR-induced G2 block while cells treated with IR/o,p'-DDD were still arrested in G2 phase. In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest. In these cells, cyclin B1 and Cdk2 proteins were examined by western blot and Cdk2 kinase activity measured by assay kit. The H295R cells treated with IR/o,p'-DDD shared an increase in cyclin B1 amount as the coimmunoprecipitation of Cdc2-cyclin B1 complex. The kinase activity also shows an increase in the treated cells with combination therapy. Moreover, in these cells, sequence analysis of p53 revealed a large deletion of exons 8 and 9. The same irreversible block on G2 phase, induced by IR/o,p'-DDD treatment, happened in H295R cells with restored wild-type p53 suggesting that this mechanism is not mediated by p53 pathway.
Endocrinology II Faculty of Medicine, University La Sapienza, Rome, Italy.
L
L
Cerquetti
B
B
Bucci
R
R
Marchese
S
S
Misiti
U
U
De Paula
R
R
Miceli
A
A
Muleti
D
D
Amendola
P
P
Piergrossi
E
E
Brunetti
V
V
Toscano
A
A
Stigliano
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D018268:Adrenocortical Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D045744:Cell Line, Tumor; D019926:Cyclin B / Q000378:metabolism; D056744:Cyclin B1; D016195:G2 Phase / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D008939:Mitotane / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D011878:Radiotherapy; D013256:Steroids / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D018931:Antineoplastic Agents, Hormonal; C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1; D012333:RNA, Messenger; D013256:Steroids; D016159:Tumor Suppressor Protein p53; D008939:Mitotane; D016203:CDC2 Protein Kinase